Last updated: March 4, 2026
What is NDC 72888-0079?
The National Drug Code (NDC) 72888-0079 corresponds to Xenleta (lefamulin), an antibiotic approved by the FDA for community-acquired bacterial pneumonia (CABP). Approved in August 2020, Xenleta offers an alternative to traditional antibiotics, with every dose delivered via IV or oral formulations.
Market Position and Competitive Landscape
Xenleta entered a crowded antibiotic market dominated by drugs such as azithromycin, levofloxacin, and moxifloxacin. Its distinguishing features include:
- Indication: Treatment of CABP in adults
- Administration: Oral and IV, simplifying transition from inpatient to outpatient care
- Mechanism of Action: Lefamulin inhibits bacterial protein synthesis, targeting Gram-positive, Gram-negative, atypical, and anaerobic bacteria
The core competitors are antibiotics with established market shares:
| Drug |
Approved Indication |
Administration |
Year Approved |
Price Range (per course) |
| Azithromycin (Zithromax) |
CABP, others |
Oral, IV |
1981 |
$50–$150 |
| Levofloxacin (Levaquin) |
CABP, others |
Oral, IV |
1996 |
$100–$250 |
| Moxifloxacin (Avelox) |
CABP, others |
Oral, IV |
1999 |
$150–$300 |
In comparison, first-approved drugs feature well-established pricing and high market penetration. Xenleta is positioned as a novel, potentially superior alternative but faces challenges in market penetration and reimbursement.
Market Size Estimates
The U.S. CABP market comprises approximately 1.1 million cases annually, with antibiotics accounting for a market value estimated at $2.5 billion in 2022[1]. Antibiotics for CABP represent about 45% of the total pneumonia treatment market.
Key factors influencing market size:
- Prescribing patterns: High outpatient prescribing sustained by oral formulations
- Adoption rate: Dependent on physician familiarity and reimbursement policies
- Pricing strategies: Premium positioning may be justified if Xenleta demonstrates superior efficacy or safety
Price Projections
Initial pricing for Xenleta was set around $2,400–$3,200 per course, which is substantially higher than comparable antibiotics, reflecting its novel mechanism and development costs.
Short-term (1–3 years)
- Price range: $2,400–$3,200 per course
- Market penetration: Limited initially due to prescriber familiarity and formulary inclusion
- Reimbursement: Likely to be a challenge; insurers may require demonstration of cost-effectiveness
Mid to long-term (4–7 years)
- Potential price adjustments: 10–20% reduction as competition increases and generics enter
- Market share growth: Possible if demonstrated superior outcomes or reduced side effects
- Projected price range: $2,000–$2,800 per course
Key factors affecting pricing dynamics
- Generic competition: Delays in generics entering the market if patents or exclusivities are maintained
- Pricing strategies: Managed care negotiations and value-based pricing
- Regulatory developments: Additional indications could expand market potential, influencing pricing strategies
Pathways to Increased Adoption
- Clinical evidence: Emphasizing advantages over existing antibiotics, such as fewer side effects or lower resistance risks
- Reimbursement efforts: Collaborations with payers to establish value-based agreements
- Market access strategies: Education for clinicians and inclusion in treatment guidelines
Summary of Price Trend Factors
| Factor |
Impact on Price |
| Competition from generics |
Downward pressure |
| Clinical advantages |
Price premiums possible |
| Reimbursement policies |
Influences initial pricing |
| Market penetration |
Effects on prices over time |
Key Takeaways
- Xenleta (lefamulin) is positioned as a novel antibiotic for CABP, with initial course prices around $2,400–$3,200.
- The drug faces competition from established antibiotics with lower prices.
- Market growth depends on clinical acceptance, reimbursement policies, and competition.
- Expected price reductions over time due to market dynamics could bring prices closer to traditional antibiotics.
- The long-term value hinges on demonstrating clear clinical benefits and achieving broad formulary access.
FAQs
-
What factors influence Xenleta’s market penetration?
Physician familiarity, reimbursement policies, clinical efficacy, and formulary inclusion are primary drivers.
-
Is Xenleta likely to be priced higher than traditional antibiotics?
Yes; initial course prices are substantially higher due to novel mechanism and development costs.
-
What is the potential for price reduction over the next 5 years?
Prices could decrease by 10–20% as generics enter and market competition intensifies.
-
How does Xenleta’s mechanism of action affect its market appeal?
Its mechanism targeting multiple bacterial types may position it as a broad-spectrum, effective alternative, potentially justifying higher pricing.
-
What are the main barriers to wider adoption?
Cost, prescriber familiarity, and reimbursement hurdles.
References
[1] IQVIA. (2022). Pharmaceutical Market Data.
